Evaluation of emotional disorders before and during treatment with interferon beta in patients with multiple sclerosis

Ouallet, J.-C.; Radat, F.; Créange, Alain; Abdellaoui, Mohamed; Heinzlef, Olivier; Giannesini, C.; Hautecœur, Patrick; Lamargue-Hamel, Delphine; Deloire, Mathilde; Brochet, Bruno; Deleglise, Anne-Sophie Jean; Lehert, Philippe

doi:10.1016/j.jns.2020.116739

Cited by 7 publications

(6 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They influence the pathological process of the disease thorough different mechanisms of action [14]. Interferon-beta (IFNbeta) is a type of treatment which influences MS progression, currently contraindicated in individuals with severe depression, due to its uncertainty regarding the implication in this comorbidity [15]. IFN-beta was associated with a higher risk of depression in some studies [16].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Influence of Depression and Anxiety on Neurological Disability in Multiple Sclerosis Patients

Văcăraș

Văcăraș²,

Nistor

et al. 2020

Behavioural Neurology

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS), affecting mostly young-aged people. As a chronic incurable disease, in most cases, it can lead to progressive neurological impairment and severe disability. Depression and anxiety are major distress factors for MS patients, being considerably aggravating elements for their functional capacity. In this study, we analysed the mood disorder distribution and the possible correlations between depression, anxiety, automatic negative thoughts, and MS disability. We took into consideration 146 MS patients, who completed a series of questionnaires: Beck Depression Inventory II (BDI-II), Endler Multidimensional Anxiety Scales-State (EMAS-S), and Automatic Thoughts Questionnaire (ATQ). The Expanded Disability Status Scale (EDSS) was used to measure the neurological disability. Of all patients, 30.1% had symptoms for depression and 11% presented suicidal thoughts. After analysing the correlation index between each variable, we found that there is a mild positive correlation between depression and the EDSS score and between anxiety and the EDSS score. A difference is found in the test scores according to the type of the MS disease. Also, automatic negative thoughts are strongly correlated with depression and anxiety, but do not mediate the path between psychological comorbidities and neurological impairment. Sociodemographic features and interferon-beta treatment were not related to the intensity of the mood disorders. The study suggests that depression and anxiety are frequently encountered among MS patients and these mental disfunctions have an impact on their disability. A proper identification of these risk factors may improve the quality of life for these patients.

show abstract

Section: Introductionmentioning

confidence: 99%

“…However, there is no connection with the serotonin metabolism in IFN-beta-treated patients [12]. In recent studies, there was no relationship between IFN-beta and emotional disturbances [15]. Some authors suggest that depression is most likely to occur in an IFN-beta-treated individual only with a past history of depressive disorders.…”

Section: Introductionmentioning

confidence: 99%

The Influence of Depression and Anxiety on Neurological Disability in Multiple Sclerosis Patients

Văcăraș

Văcăraș²,

Nistor

et al. 2020

Behavioural Neurology

View full text Add to dashboard Cite

show abstract

“…Six of the studies were clustered to the left of the overall prevalence. These studies had the largest populations and were weighted the highest with the exception of the study by Ouallet et al [33] which had a small population of 70 and a small prevalence of 0.01, and the study by Eliasen et al [31] which had a population of 362 and the second highest prevalence of 0.13. Four studies were weighted more than 9% and had a total weight of 37.91%.…”

Section: Prevalencementioning

confidence: 99%

Multiple Sclerosis and Suicide Attempts: A Review including a Meta-Analysis of Prevalence

d’Andrade,

Larsen,

Stenager

et al. 2023

Acta Neurologica Scandinavica

View full text Add to dashboard Cite

Background. Multiple sclerosis is an autoimmune inflammatory demyelinating disorder, and persons diagnosed with multiple sclerosis have a shorter life expectancy than the general population. Recent meta-analyses have examined the association between MS and suicide and between MS and suicidal ideation. The objective of the present review was to examine if MS is associated with a higher risk of suicide attempt. We hypothesised that MS patients were at increased risk of suicide attempts. Methods. Four databases (PubMed including MEDLINE, EMBASE, Web of Science, and PsycINFO) were searched systematically for studies assessing the risk of attempted suicide in people with MS. Eligibility criteria were studies designed as cohort, case-control, or cross-sectional studies with attempted suicide as the outcome and published in English. Lifetime prevalence of suicide attempt was calculated through a meta-analysis, and the results were presented as a forest plot. Sensitivity analyses were used to investigate the heterogeneity among studies. Results. 13 studies were identified from 533 records, providing a total population of 50,004 participants of whom 599 had attempted suicide. The weighted overall prevalence of suicide attempts among people with MS was 0.04 (95% CI 0.02-0.06) with a Cochran’s Q value of 591.05, which rejected the null hypothesis of homogeneous studies. The performed sensitivity analysis resulted in an I 2 of 81% as the lowest possible value, which still indicated a high level of heterogeneity. Conclusion. To our knowledge, this is the first study to examine the association between MS and suicide attempts in a meta-analysis. The results suggest a significant association between MS and suicide attempts. However, the small number of the included studies and the heterogeneous nature of these studies indicate a need for more studies based on more homogeneous samples.

show abstract

“…leczenie IFN-β wpływa na zmniejszenie objawów depresji (Ouallet et al, 2020). W badaniu autorów niniejszej pracy uzyskano poprawę nastroju w grupie chorych leczonych IFN-β, co może mieć związek z regularnym przyjmowaniem leków przeciwdepresyjnych.…”

Section: Wnioskiunclassified

Assessment of fatigue, cognition and depression in correlation with the applied immunomodulating treatment based on the Lodz registry of patients with multiple sclerosis

Janiak¹,

Bednarski²,

Głąbiński³

2020

Aktualn Neurol

View full text Add to dashboard Cite

Introduction: Multiple sclerosis is the most common chronic inflammatory demyelinating disease of the central nervous system, mainly affecting young people. A breakthrough in the treatment of multiple sclerosis was the introduction of immunomodulating drugs that affect the natural course of the disease as well as improve the quality of life of patients. Aim of the study: To establish a possible association between the level of cognitive disorders, fatigue, depression and the used immunomodulating treatment (disease-modifying treatment) in patients with the relapsing-remitting form of multiple sclerosis. Materials and methods: The research material consisted of 169 patients with multiple sclerosis (diagnosed according to the 2010 McDonald criteria) with the relapsing-remitting form of multiple sclerosis. The subjects were divided into two groups: the test group – receiving disease-modifying treatment (n = 132), undergoing immunomodulatory therapy, and the control group – untreated multiple sclerosis (n = 37), patients who did not receive immunomodulating therapy. Methods: multiple sclerosis patient registry – RejSM questionnaire; Beck Depression Inventory II (BD-II); postural function assessment – MMSE (Mini-Mental State Examination); FACIT quality of life (Functional Assessment of Chronic Illness Therapy – Fatigue; FACIT Fatigue Scale, FFS). Patients from both groups underwent tests (BD-II, MMSE, FFS) at two time points: at baseline (I) and after 12 months of immunomodulating treatment (II). Results: The post-hoc test (Tukey’s) showed a decrease in Beck Depression Inventory and FACIT-F scores which was statistically significant only in the disease-modifying treatment group. The results indicate that the use of interferon beta causes a significant reduction in depression (p < 0.0001) and fatigue (p < 0.0001) between the measured time points. The FACIT scores were significantly different between the time points for those treated with glatiramer acetate (p < 0.0001). In the case of MMSE evaluation, the patients receiving disease-modifying treatment did not differ significantly between the beginning and end of the study (p = 0.1210). Conclusions: The results of our research indicate that disease-modifying treatment used in patients with the relapsing-remitting form of multiple sclerosis has a beneficial effect in terms of improving their quality of life and reducing the symptoms of depression.

show abstract

Evaluation of emotional disorders before and during treatment with interferon beta in patients with multiple sclerosis

Cited by 7 publications

References 34 publications

The Influence of Depression and Anxiety on Neurological Disability in Multiple Sclerosis Patients

The Influence of Depression and Anxiety on Neurological Disability in Multiple Sclerosis Patients

Multiple Sclerosis and Suicide Attempts: A Review including a Meta-Analysis of Prevalence

Assessment of fatigue, cognition and depression in correlation with the applied immunomodulating treatment based on the Lodz registry of patients with multiple sclerosis

Contact Info

Product

Resources

About